Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Small Swedish Biotech Cyxone’s US CEO Has ‘Big Plans’

Listing On Nasdaq Stockholm, Growing Pipeline And Finding Partners

Executive Summary

Swedish biotech Cyxone’s CEO tells Scrip about its aims to become a cutting-edge developer of disease-modifying treatments for rheumatoid arthritis and multiple sclerosis, but says the Scandinavian industry needs a ‘mindset change’.

You may also be interested in...



Ipsen Buys Into BAX Inhibitor, Targeting Certain Cancers

Ipsen has inked a worldwide collaboration pact with BAKX Therapeutics to research, develop, manufacture and commercialize the biotech’s asset BKX-001 as a potential treatment for leukemia, lymphoma and solid tumors.

Roche R&D Spending Surge Reflects In-House Innovation, M&A Prices

A surprise surge in Roche's R&D spending this year reflects high quality in-house innovation opportunities as well as high prices for external M&A targets, management said.

Roche Deals With Huge Gantenerumab Curiosity At H1 Update

Roche unveiled a strong Q2 performance driven by new medicines and continued strong growth from its diagnostics division but analysts were most keen for clues on plans for gantenerumab, now in Phase III studies for Alzheimer’s disease.

Topics

Related Companies

UsernamePublicRestriction

Register

SC144678

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel